Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AVI-4065 Injection
AVI-4065 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVI-4065 Injection | DRUG | - |
Inclusion Criteria: * Adult males 18 years to 64 years of age; * Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range) * Signed and dated written informed consent form; and * Willing to partici...
AVI-4065 is an investigational small molecule being developed by Sarepta Therapeutics, Inc. (ticker: SRPT) for encephalitis, a neurological condition. It is in Phase 1 clinical development and has been studied in a single completed trial. AVI-4065 is also known as AVI-4065 Injection.
AVI-4065 is being studied for encephalitis, a neurological condition. It is an investigational therapy and has not been approved for any indication. The only clinical trial of AVI-4065 enrolled healthy volunteers, not patients with encephalitis.
AVI-4065 is being developed by Sarepta Therapeutics, Inc., which trades under the ticker SRPT. Sarepta is the sponsor of the clinical program for AVI-4065.
AVI-4065 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program consists of one completed trial, and no active trials are currently listed.
AVI-4065 has been studied in one completed Phase 1 trial, NCT00381433, titled "Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid." The trial enrolled 12 healthy male volunteers in the United States and was uncontrolled, with no randomization or blinding.
Yes, AVI-4065 Injection is an alternative name for AVI-4065. Both refer to the same investigational small molecule developed by Sarepta Therapeutics, Inc. (ticker: SRPT) for encephalitis.